Active, not recruitingPhase 2NCT07376317

Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)

Studying Neuroendocrine neoplasm

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Instituto do Cancer do Estado de São Paulo
Intervention
Pembrolizumab(drug)
Enrollment
29 target
Eligibility
18 years · All sexes
Timeline
20212027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07376317 on ClinicalTrials.gov

Other trials for Neuroendocrine neoplasm

Additional recruiting or active studies for the same condition.

See all trials for Neuroendocrine neoplasm

← Back to all trials